| Literature DB >> 7139641 |
E Hernandez, N B Rosenshein, J Pino y Torres, J Villar, F C Grumbine, D S Ettinger, M B Dillon, J L Klein, S E Order.
Abstract
Nine patients with advanced epithelial ovarian cancer, classified as either stage III with macrometastatic residual disease or stage IV, received combination chemotherapy in conjunction with ip rabbit-derived human ovarian antitumor serum (HOATS). The HOATS regimen consisted of the ip instillation of 100 ml of ovarian antitumor serum on Days 1 and 3 of the first chemotherapy cycle. Side effects attributable to HOATS were low-grade fever in three patients and diffuse skin rash in two. The 1-year cumulative survival was 87%, with a clinical response rate of 80%. No significant toxic reactions to HOATS have been observed. Continuation of the present study seems justified.Entities:
Mesh：
Substances：
Year: 1982 PMID： 7139641
Source DB: PubMed Journal: Cancer Treat Rep ISSN： 0361-5960